Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
MENLO PARK, Calif., Feb. 22, 2017 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the market close. Geron’s management will also host a conference call for analysts and investors on Wednesday, March 1, 2017, at 4:30 p.m. Eastern Time to discuss the company’s fourth quarter and annual results as well as recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 53505663. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available through the Investors section of our website at www.geron.com or at http://edge.media-server.com/m/p/ouvh9xwx. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 1, 2017.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
